Bio-Techne

Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company's brands include flagship R&D Systems (Research and Diagnostic Systems Inc.), Novus Biologicals, Tocris Bioscience, ProteinSimple, Exosome Diagnostics, BiosPacific, Cliniqa, Advanced Cell Diagnostics, RNA Medical, Bionostics, and Boston Biochem. The company's products are used in both clinical and research contexts. The company was co-founded as a "hematology controls developer" by Dr. Roger C. Lucas, who presently serves as its Chief Scientific Advisor.
Bio-Techne is listed on the NASDAQ under the ticker symbol TECH. Writing for Forbes from an investor's perspective, John Reese praised the management team saying it "...appears to be doing a solid job...", a sentiment echoed by Philip van Doorn, writing for Dow Jones MarketWatch. Interviewing investor Edward B. White for "The New York Times", Carole Gould noted that White thought the chief executive, Thomas Oland, was a "deeply committed scientist."
Beginning in 2013, the company's chief executive officer was Charles (Chuck) Kummeth, who had previously been employed by 3M and Thermo Fisher Scientific.
In an article by the Star Tribune, Joe Carlson wrote "Analysts like how Bio-Techne is growing, combining well-considered acquisition targets with the company's long-running reputation for producing top-quality raw proteins and antibodies for use in research."